News

CureVac N.V. a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) and Celonic Group, a premium biopharmaceutical…
Read More...

Novartis announced that the European Commission has approved Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined…
Read More...

Amgen Inc. and Rodeo Therapeutics Corporation announced an agreement under which Amgen will acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops…
Read More...

Tarsus Pharmaceuticals, Inc. a late clinical-stage biopharmaceutical company, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China…
Read More...

Hansa Biopharma AB announced that they have entered into a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two…
Read More...

Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional…
Read More...

Humanigen, Inc. a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab,…
Read More...

Eli Lilly and Company, Vir Biotechnology, Inc. and GlaxoSmithKline plc announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to…
Read More...

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make…
Read More...

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or…
Read More...

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced the submission of an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA)…
Read More...

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that it signed a…
Read More...

Bright Peak Therapeutics Inc., a biotechnology company developing next generation immunotherapies for cancer and autoimmune disease, and Ajinomoto Co., Inc. ("Ajinomoto Co."), a leading…
Read More...

Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing transformative biologics such as vaccines and therapeutics for the world's most debilitating…
Read More...

Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are…
Read More...

A collaboration among scientists from UCLA and other universities in California, Delaware and Germany, as well as a German pharmaceutical company, has singled out a compound that shows…
Read More...

Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, announced the successful closing of a EUR35 million Series B financing. New investors Hadean…
Read More...

Vertex Pharmaceuticals Incorporated announced that the Australian Therapeutic Goods Administration (TGA) has approved the use of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and…
Read More...

Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, announced several important…
Read More...

A broad coalition of biopharmaceutical and technology leaders announced a new strategic collaboration to promote new and updated standards for advanced therapies. The new collaboration,…
Read More...